Abstract
Recent clinical studies have established an important role of angiotensin converting enzyme inhibitors (ACE-I) as a tool for renal protection. Although angiotensin receptor antagonists (AII-A) share the common property with ACE-I with regard to blockade of angiotensin activity via angiotensin type 1 receptors (AT1), AII-A is also reported to stimulate AT2 that plausibly activates nitric oxide production within renal medulla and augments synthesis of vasodilatory P450-metabolites in renal afferent arterioles. In contrast, AII-A is reported to have no effect on bradykinin activity. Results obtained in experimental animals indicate that AII-A effectively prevents the progression of renal injury. Several clinical studies are in progress, and the preliminary results suggest that AII-A has potent renal protective action in a variety of renal disorders.
| Original language | English |
|---|---|
| Pages (from-to) | 1164-1167 |
| Number of pages | 4 |
| Journal | Nippon rinsho. Japanese journal of clinical medicine |
| Volume | 57 |
| Issue number | 5 |
| Publication status | Published - 1999 |
Fingerprint
Cite this
Potential role of angiotensin receptor antagonists in renal protection. / Hayashi, K.; Matsuda, H.; Honda, M.; Saruta, T.
In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 57, No. 5, 1999, p. 1164-1167.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Potential role of angiotensin receptor antagonists in renal protection
AU - Hayashi, K.
AU - Matsuda, H.
AU - Honda, M.
AU - Saruta, T.
PY - 1999
Y1 - 1999
N2 - Recent clinical studies have established an important role of angiotensin converting enzyme inhibitors (ACE-I) as a tool for renal protection. Although angiotensin receptor antagonists (AII-A) share the common property with ACE-I with regard to blockade of angiotensin activity via angiotensin type 1 receptors (AT1), AII-A is also reported to stimulate AT2 that plausibly activates nitric oxide production within renal medulla and augments synthesis of vasodilatory P450-metabolites in renal afferent arterioles. In contrast, AII-A is reported to have no effect on bradykinin activity. Results obtained in experimental animals indicate that AII-A effectively prevents the progression of renal injury. Several clinical studies are in progress, and the preliminary results suggest that AII-A has potent renal protective action in a variety of renal disorders.
AB - Recent clinical studies have established an important role of angiotensin converting enzyme inhibitors (ACE-I) as a tool for renal protection. Although angiotensin receptor antagonists (AII-A) share the common property with ACE-I with regard to blockade of angiotensin activity via angiotensin type 1 receptors (AT1), AII-A is also reported to stimulate AT2 that plausibly activates nitric oxide production within renal medulla and augments synthesis of vasodilatory P450-metabolites in renal afferent arterioles. In contrast, AII-A is reported to have no effect on bradykinin activity. Results obtained in experimental animals indicate that AII-A effectively prevents the progression of renal injury. Several clinical studies are in progress, and the preliminary results suggest that AII-A has potent renal protective action in a variety of renal disorders.
UR - http://www.scopus.com/inward/record.url?scp=0033129130&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033129130&partnerID=8YFLogxK
M3 - Article
C2 - 10361451
AN - SCOPUS:0033129130
VL - 57
SP - 1164
EP - 1167
JO - Nihon rinsho. Japanese journal of clinical medicine
JF - Nihon rinsho. Japanese journal of clinical medicine
SN - 0047-1852
IS - 5
ER -